Nishida Naoshi, Nishimura Takafumi, Nagasaka Takeshi, Ikai Iwao, Goel Ajay, Boland C Richard
Department of Internal Medicine, Division of Gastroenterology, Sammons Cancer Center, Baylor Research Institute, Baylor University Medical Center, Dallas, Texas, USA.
Cancer Res. 2007 May 15;67(10):4586-94. doi: 10.1158/0008-5472.CAN-06-3464.
Hepatocellular carcinoma (HCC) with p53 mutations is usually characterized by extensive chromosomal instability (CIN), whereas those with beta-catenin mutations have relatively less CIN and the molecular pathogenesis of these tumors is unknown. Methylation of CpG dinucleotides in the promoters of cancer-related genes is another characteristic feature of HCCs. The aim of this study was to determine the contribution of the methylator phenotype to HCC and its relationship to genomic instability. Fractional allelic loss (FAL) was determined using 400 microsatellite markers in 81 HCCs and 77 corresponding noncancerous livers as a measure of CIN. Methylation of 21 genetic loci was quantitated using combined bisulfite restriction analysis. Using hierarchical clustering analysis based upon the quantification of methylation levels, all HCCs were segregated into two groups characterized by either limited or extensive methylation. Mutations in the beta-catenin and p53 genes were determined by DNA sequencing. We found that the methylation levels were significantly higher in the HCCs than in noncancerous livers in 18 of the 21 loci (P values ranged from 0.035 to <0.0001). Among 18 loci, elevated levels of methylation at nine loci were significantly associated with beta-catenin mutations (P values ranged from 0.02 to <0.0001). In addition, the presence of beta-catenin mutations was associated with HCCs in the extensive methylation group (P < 0.0001), whereas p53 mutations correlated with high FAL scores (P = 0.0036). These data suggest that HCCs can be classified into two distinct categories based upon promoter methylation, CIN, and mutations of cancer-related genes. HCCs with extensive methylation harbor frequent beta-catenin mutations, whereas HCCs with high levels of CIN are associated with p53 mutations, suggesting the presence of two independent pathways for the pathogenesis of HCC.
具有p53突变的肝细胞癌(HCC)通常具有广泛的染色体不稳定性(CIN)特征,而具有β-连环蛋白突变的HCC的CIN相对较少,且这些肿瘤的分子发病机制尚不清楚。癌症相关基因启动子中CpG二核苷酸的甲基化是HCC的另一个特征。本研究的目的是确定甲基化表型对HCC的影响及其与基因组不稳定性的关系。使用400个微卫星标记在81例HCC和77例相应的非癌肝组织中测定等位基因缺失分数(FAL),作为CIN的指标。使用联合亚硫酸氢盐限制性分析对21个基因位点的甲基化进行定量。基于甲基化水平的定量,采用层次聚类分析将所有HCC分为甲基化有限或广泛的两组。通过DNA测序确定β-连环蛋白和p53基因的突变。我们发现,21个位点中有18个位点的HCC甲基化水平显著高于非癌肝组织(P值范围为0.035至<0.0001)。在18个位点中,9个位点甲基化水平升高与β-连环蛋白突变显著相关(P值范围为0.02至<0.0001)。此外,β-连环蛋白突变的存在与广泛甲基化组中的HCC相关(P<0.0001),而p53突变与高FAL评分相关(P = 0.0036)。这些数据表明,HCC可根据启动子甲基化、CIN和癌症相关基因突变分为两个不同的类别。甲基化广泛的HCC频繁发生β-连环蛋白突变,而CIN水平高的HCC与p53突变相关,提示HCC发病机制存在两条独立的途径。